MedTrace Logo

Effect on Cognitive Function of a Treatment With Aripiprazole

NCT00329810 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2013-11-08

No results posted yet for this study

Summary

To evaluate the effectiveness of Aripiprazole after 12 weeks of therapy for Schizophrenic patients.

Conditions

Interventions

DRUG

Aripiprazole

Tablets, oral, 15 mg, once daily, 12 weeks.

Sponsors & Collaborators

  • Otsuka America Pharmaceutical

    collaborator INDUSTRY

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2006-03-31
Completion
2006-03-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00329810 on ClinicalTrials.gov